share_log

弘毅文化集團:二零二四年中期報告

HONY MEDIA: INTERIM REPORT 2024

HKEX ·  Sep 26 16:30

Summary by Futu AI

弘毅文化集團(前稱華誼騰訊娛樂)於二零二四年上半年收入錄得4.89億港元,較去年同期下降22%。主要收入來源為醫療產業數字化運營服務「醫智諾」,期內收入為3.73億港元,下降23%。智慧健康服務平台「獴哥健康」收入為1.16億港元,下跌21%。公司虧損收窄31%至約4,618萬港元。二零二四年一月,醫智諾聯合多家國內大型藥企在上海成立醫藥產業首個標準創新聯合體,推動生物醫藥產業數字化轉型。公司未派發股息,並於三月發行可換股債券,籌集資金約1.18億港元。截至二零二四年六月三十日,公司無重大或然負債。
弘毅文化集團(前稱華誼騰訊娛樂)於二零二四年上半年收入錄得4.89億港元,較去年同期下降22%。主要收入來源為醫療產業數字化運營服務「醫智諾」,期內收入為3.73億港元,下降23%。智慧健康服務平台「獴哥健康」收入為1.16億港元,下跌21%。公司虧損收窄31%至約4,618萬港元。二零二四年一月,醫智諾聯合多家國內大型藥企在上海成立醫藥產業首個標準創新聯合體,推動生物醫藥產業數字化轉型。公司未派發股息,並於三月發行可換股債券,籌集資金約1.18億港元。截至二零二四年六月三十日,公司無重大或然負債。
Huayi Tencent Entertainment Group (formerly known as Huayi Tencent) recorded a revenue of 0.489 billion Hong Kong dollars in the first half of 2024, a 22% decrease from the same period last year. The main source of revenue is the digital operation service 'Yi Zhi Nuo' in the medical industry, with revenue of 0.373 billion Hong Kong dollars during the period, a 23% decrease. The revenue of the smart health service platform 'Mole Brother Health' was 0.116 billion Hong Kong dollars, a 21% decline. The company narrowed its losses by 31% to approximately 46.18 million Hong Kong dollars. In January 2024, Yi Zhi Nuo, in collaboration with several major domestic pharmaceutical companies, established the first standard innovation consortium in the biomedical industry in Shanghai to promote digital transformation. The company did not distribute dividends and issued convertible bonds in March to raise approximately 0.118 billion Hong Kong dollars. As of June 30, 2024, the company has no significant contingent liabilities.
Huayi Tencent Entertainment Group (formerly known as Huayi Tencent) recorded a revenue of 0.489 billion Hong Kong dollars in the first half of 2024, a 22% decrease from the same period last year. The main source of revenue is the digital operation service 'Yi Zhi Nuo' in the medical industry, with revenue of 0.373 billion Hong Kong dollars during the period, a 23% decrease. The revenue of the smart health service platform 'Mole Brother Health' was 0.116 billion Hong Kong dollars, a 21% decline. The company narrowed its losses by 31% to approximately 46.18 million Hong Kong dollars. In January 2024, Yi Zhi Nuo, in collaboration with several major domestic pharmaceutical companies, established the first standard innovation consortium in the biomedical industry in Shanghai to promote digital transformation. The company did not distribute dividends and issued convertible bonds in March to raise approximately 0.118 billion Hong Kong dollars. As of June 30, 2024, the company has no significant contingent liabilities.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.